Bioscribe

Today on #RareDiseaseDay, we recognize the millions of individuals and families impacted by rare diseases —including our colleague Colin Sanford, whose daughter has a condition caused by a rare mutation in the KCNQ2 gene. KCNQ2-related disorders range from severe early-onset epilepsies, known as developmental and epileptic encephalopathies (DEEs), to milder forms referred to as self-limited (benign) neonatal epilepsies. These conditions can profoundly affect patients and their families, making research and awareness critical. Colin not only brings his expertise to Bioscribe but also serves as a board member of the KCNQ2 Cure Alliance, helping drive research, new therapy development, and advocacy for families navigating these challenges. At Bioscribe, we are proud to support life sciences companies working to better understand rare diseases and develop treatments that can change lives. Today, we stand with the entire rare disease community in the fight for greater awareness, research, and cures! #RareDiseaseDay2025 #StandUpForScience

Today on #RareDiseaseDay, we recognize the millions of individuals and families impacted by rare diseases —including our colleague Colin Sanford, whose daughter has a condition caused by a rare mutation in the KCNQ2 gene. KCNQ2-related disorders range from severe early-onset epilepsies, known as developmental and epileptic encephalopathies (DEEs), to milder forms referred to as self-limited (benign) neonatal epilepsies. These conditions can profoundly affect patients and their families, making research and awareness critical. Colin not only brings his expertise to Bioscribe but also serves as a board member of the KCNQ2 Cure Alliance, helping drive research, new therapy development, and advocacy for families navigating these challenges. At Bioscribe, we are proud to support life sciences companies working to better understand rare diseases and develop treatments that can change lives. Today, we stand with the entire rare disease community in the fight for greater awareness, research, and cures! #RareDiseaseDay2025 #StandUpForScience

Congratulations to #TeamEikon on this well-deserved recognition of your pioneering work to develop transformative new medicines! This milestone reflects the incredible dedication, innovation, and scientific excellence that drive your mission forward. Bioscribe is proud to support such a deeply talented team as you continue to push the boundaries of drug discovery and create a healthier world. ????

The Bioscribe team stands in solidarity with the nationwide Stand Up for Science rallies taking place on March 7th, championing science as a public good. Our nation's leadership in research has delivered remarkable benefits in health, safety, and innovation —and protecting this legacy while ensuring researchers can freely follow the evidence is essential for progress. For more than 25 years, Bioscribe has proudly supported pioneering scientists and the innovative companies they’ve built, from the trailblazers behind the first biotech drugs and the tools that enabled the Human Genome Project to today's leaders advancing cutting-edge research AI technologies, molecular diagnostics, and new drug development. Together with our friends and colleagues in the life sciences industry, we urge policymakers to secure robust research funding, safeguard open inquiry, and foster an inclusive scientific community, because science is the engine that drives the breakthroughs essential for improving life for all of us. #standupforscience2025 #sciencenotsilence #scienceforall?

Need help with your 2025 PR planning? Book a complimentary consultation and gain insights on how to optimize your communications program from Bioscribe's nearly 30 years of experience supporting life science innovators. Whether you're aiming to grow awareness through media coverage, launch impactful campaigns for new products, or boost executive visibility, the Bioscribe team of experienced communications strategists, media specialists and content creators is here to help. Not sure what the best timing is to come out of stealth or introduce your company? We can advise you on that too! Wherever you are in your company/product lifecycle, our all senior-level team specializes in creating scalable, results-driven communications programs tailored to fit your goals and budget, with no retainers required and no monthly minimums. It’s not too late to set your 2025 communications plan in motion, so reach out to [email protected] and we'll be happy to give you some initial ideas and advice, with no obligation! www.Bioscribe.com #BiotechPR #SciComms #NewYearNewGoals #PRPlanning #LifeSciences

Congratulations to Ultivue, by Vizgen, and Oxford Nanopore Technologies for being recognized by The Scientist magazine with Top Ten Innovations of 2024! Vizgen’s STARVUE Image Data Science Platform and Oxford Nanopore’s Direct RNA Sequencing solution are groundbreaking tools advancing our understanding of complex biology. STARVUE empowers researchers to unravel the intricacies of tumor microenvironments with high-definition spatial biology, while Oxford Nanopore’s innovations in sequencing enable a more complete picture of the RNA landscape. At Bioscribe, we’re proud to partner with pioneering life sciences companies, helping to amplify their incredible contributions to medical research and innovation. Here’s to continuing to push the boundaries of science and technology! Read more about these innovative products: https://lnkd.in/eaqf-mMb #AmazingClients #LifeSciences #SciComm #BiotechPR

Congratulations to the Vizgen team for securing the #1 private company spot on Genetic Engineering & Biotechnology News' 2024 list of Top Spatial Biology Companies!?Bioscribe is honored to partner with this innovative team and we are excited to support their continued success in 2025 and beyond! #InnovativeClients #ClientNews #PR #LifeScienceComms #LifesScienceMarketing #Biotech #LifeSciences

The trade media are often considered second fiddle to the buzzier top-tier outlets, but they are by no means less important to your overall earned media strategy. After 27 years working in the life sciences industry, the Bioscribe team has seen time and time again how this kind of targeted exposure is a perfect complement to the higher-profile articles placed in the top-tier media, allowing you to sustain momentum and credibility among key decision-makers and influencers. Read more about the 5 reasons why we believe that trade journalists, with their deeper understanding of the industry’s inner workings, can provide sophisticated and nuanced coverage that resonates with the often skeptical life science-focused audiences. #PR #MediaRelations #SciComms #BiotechPR #LifeSciencePR

Complex DNA is, in a word, complex. This excellent primer from Ansa co-founder & CSO, Dan Lin-Arlow, breaks it down and highlights how enzymatic DNA synthesis is paving the way forward for the complex DNA that is essential to driving innovation in the bioeconomy. #SynBioBeta2024 #InnovativeClients

PR tip: Don't forget to showcase your company's small wins between big milestones ? Read more PR perspectives from Nicole Litchfield, CEO and founder of our partners at Bioscribe, in the latest issue of The Pitch: https://lnkd.in/gnyPWtiA